← Retour à la liste complète des publications

YES, a novel therapeutic target in hepatocellular carcinoma.

Lapouge M, Meloche S

Signaling and Cell Growth Laboratory, Institute for Research in Immunology and Cancer, Montreal, Quebec, Canada.

Identification of dominant, actionable oncogenic signaling pathways is key to guide the development of new targeted treatments for advanced-stage hepatocellular carcinoma (HCC). We have recently unveiled a novel YES-YAP/TAZ signaling axis involved in liver cancer development. Our study identifies the tyrosine kinase YES as a potential therapeutic target in HCC.

Mol Cell Oncol 2022;9(1):2069993.

Pubmed ID: 35529900

Suivez l'IRIC

Logo UdeM